8-K filings / November 18, 2026
TEVA PHARMACEUTICAL INDUSTRIES LTD: A change of officers or directors
TEVA PHARMACEUTICAL INDUSTRIES LTD filed a current report (Form 8-K) with the SEC on November 18, 2026. It reports a change of officers or directors.
Item 5.02
Officers and directors
-
Leaves
Eric Hughes, Executive Vice President, Global R&D and Chief Medical Officer
From the filing
Source
“On November 17, 2026, Dr. Eric Hughes, Executive Vice President, Global R&D and Chief Medical Officer, notified Teva Pharmaceutical Industries Ltd. (“Teva” or the “Company”) of his intention to resign.”
Read by code from this sentence of the filing.
Not investment advice.Read the filing on SEC.gov
Facts read from the filing's own text; a fact the filing does not state clearly is left out. All documents of this filing on SEC.gov.